Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical 1Q Net Fell 19% on Higher Research Expenses

share with twitter share with LinkedIn share with facebook
04/29/2020 | 07:00am EDT

By Kosaku Narioka

Shanghai Fosun Pharmaceutical (Group) Co. said Wednesday that first-quarter net profit fell 19% from a year earlier due partly to higher research expenses and slower earnings from affiliates.

The Chinese pharmaceutical company said net profit fell to 577.2 million Chinese yuan ($81.53 million) for the quarter ended March 31 from CNY712.3 million a year earlier.

Shanghai Fosun Pharmaceutical said revenue fell 13% to CNY5.88 billion from CNY6.73 billion a year earlier, while research and development costs increased and administrative expenses rose.

Shanghai Fosun Pharmaceutical also said that the Covid-19 pandemic weighed on earnings from associates and joint ventures.

 

Write to Kosaku Narioka at kosaku.narioka@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. -2.11% 6.5 Delayed Quote.20.73%
JUST GROUP PLC -2.54% 47.66 Delayed Quote.-38.10%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. 2.64% 35.33 End-of-day quote.32.82%
THE NEW HOME COMPANY INC. 4.06% 3.33 Delayed Quote.-31.33%
WILL GROUP, INC. 5.03% 668 End-of-day quote.-46.65%
share with twitter share with LinkedIn share with facebook
Latest news on SHANGHAI FOSUN PHARMACEUTI
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
06/29Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech
RE
04/29Shanghai Fosun Pharmaceutical 1Q Net Fell 19% on Higher Research Expenses
DJ
03/30Shanghai Fosun Pharmaceutical 2019 Net Profit Rises 23%
DJ
03/20SHANGHAI FOSUN PHARMACEUTICAL GROUP : annual earnings release
03/18SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - the progress of the pla..
PU
03/18SHANGHAI FOSUN PHARMACEUTICAL : Date of board meeting(h shares)
PU
03/17Pfizer, BioNTech to co-develop potential coronavirus vaccine
RE
03/16BioNTech in China alliance with Fosun over potential coronavirus vaccine
RE
03/15SHANGHAI FOSUN PHARMACEUTICAL : OVERSEAS REGULATORY ANNOUNCEMENT - Announcement ..
PU
More news
Financials
Sales 2020 32 408 M 4 619 M 4 619 M
Net income 2020 3 526 M 503 M 503 M
Net Debt 2020 13 549 M 1 931 M 1 931 M
P/E ratio 2020 25,4x
Yield 2020 1,16%
Capitalization 85 189 M 12 141 M 12 141 M
EV / Sales 2019
EV / Sales 2020 3,05x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 31,82 CNY
Last Close Price 35,33 CNY
Spread / Highest target 18,9%
Spread / Average Target -9,93%
Spread / Lowest Target -39,3%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP